Adlai Nortye Group Ltd. (ANL)

Adlai Nortye Group Ltd., a clinical-stage biopharmaceutical company, engages in the discovery and development of cancer therapies. The company's pipeline centers on RAS-targeting therapies and next-generation cancer immunotherapies. Its RAS-targeting programs include AN9025, an oral pan-RAS(ON) inhibitor for RAS-driven cancers, and AN4035, a CEACAM5-targeting antibody-drug conjugate that delivers a pan-RAS(ON) inhibitor to tumors. Its immunotherapy programs include AN8025, a tri-functional fusion protein (aPD-L1 x CD86 variant x LAG3 variant) that modulates T-cells and antigen-presenting cells; AN0025, a small molecule EP4 antagonist; and AN4005, an oral small-molecule PD-L1 inhibitor. The company supports its pipeline through an immuno-oncology research and development platform with operations in the United States and China. Adlai Nortye Group Ltd. was formerly known as Adlai Nortye Ltd. and changed its name to Adlai Nortye Group Ltd. in July, 2026. Adlai Nortye Group Ltd. was founded in 2004 and is based in Singapore.